Potential Dapagliflozin Benefit Post-MI Is Not a ' Mandate ' Potential Dapagliflozin Benefit Post-MI Is Not a ' Mandate '

A registry trial of SGLT-2 inhibition in low-risk patients after an MI showed some benefit in preventing future events, but a larger study would be warranted to further validate the signal.MDedge News
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology News Source Type: news